During the past decade, Hamamatsu University Hospital conducted 54 clinical trials. In the 10-year time frame, 54 clinical trials started and 17 clinical trials were completed, i.e. on average, 31.5% percent of trials that started reached the finish line to date. In the past 5 years, 32 clinical trials started and 15 clinical trials were completed. i.e. 46.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hamamatsu University Hospital" #1 sponsor was "Pfizer" with 18 trials, followed by "Boehringer Ingelheim" with 6 trials sponsored, "Eli Lilly and Company" with 4 trials sponsored, "Janssen Pharmaceutical K.K." with 4 trials sponsored and "Janssen Research & Development, LLC" with 4 trials sponsored. Other sponsors include 21 different institutions and companies that sponsored additional 23 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hamamatsu University Hospital" #1 collaborator was "Astellas Pharma Inc" with 2 trials as a collaborator, "Eli Lilly and Company" with 2 trials as a collaborator, "Incyte Corporation" with 2 trials as a collaborator, "Japan Lung Cancer Society" with 2 trials as a collaborator and "Arena is a wholly owned subsidiary of Pfizer" with 1 trials as a collaborator. Other collaborators include 1 different institutions and companies that were collaborators in the rest 11 trials.

According to Clinical.Site data, the most researched conditions in "Hamamatsu University Hospital" are "Alopecia Areata" (5 trials), "Prostatic Neoplasms" (5 trials), "Lung Diseases, Interstitial" (3 trials), "Psoriasis" (3 trials) and "Carcinoma, Renal Cell" (2 trials). Many other conditions were trialed in "Hamamatsu University Hospital" in a lesser frequency.

Most popular intervention types in "Hamamatsu University Hospital" are "Drug" (52 trials), "Biological" (10 trials), "Other" (5 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (25 trials), "Nintedanib" (4 trials), "BMS-986165" (3 trials), "Enzalutamide" (3 trials) and "Pembrolizumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Hamamatsu University Hospital" are 49 trials for "All" genders, 9 trials for "Male" genders and 4 trials for "Female" genders.

Currently, there are NaN active trials in "Hamamatsu University Hospital". undefined are not yet recruiting, 12 are recruiting, 21 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 25 completed trials in Hamamatsu University Hospital, 1 suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Hamamatsu University Hospital, 1 "Phase 1" clinical trials were conducted, 15 "Phase 2" clinical trials and 37 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".